GlassScriptPhysician profile
Amal Adely
NPI 1447031695
$2,926.11
in general payments reported to CMS, 2019-2025
21 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $65.55 · 2024: $1,369 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,926.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $637.93 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $413.77 | 2024-2025 | Caplyta |
| Alkermes, INC. | $366.54 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $259.09 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $235.81 | 2024-2025 | Spravato |
| Neurocrine Biosciences, INC. | $222.63 | 2023-2025 | Ingrezza |
| Corium, LLC | $156.71 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $153.09 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $79.55 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $66.47 | 2024-2025 | Rexulti |
| Biogen, INC. | $52.17 | 2024-2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $45.15 | 2024 | Relexxii |
| Vanda Pharmaceuticals INC. | $41.52 | 2024-2025 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $35.92 | 2024-2025 | Trintellix |
| Tempus Ai, INC | $26.76 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $23.81 | 2024 | |
| Neos Therapeutics, LP | $23.53 | 2024 | Adzenys Xr-Odt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.38 | 2024 | |
| Collegium Pharmaceutical, INC. | $22.46 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $22.15 | 2023 | Quviviq |
| Bausch Health US, LLC | $17.67 | 2025 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amal Adely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.